New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2012
06:36 EDTCBLICleveland BioLabs initiated with an Outperform at Oppenheimer
Target $3.
News For CBLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
07:38 EDTCBLICleveland BioLabs says entolimod shown to suppress metastasis
Subscribe for More Information
February 2, 2016
08:15 EDTCBLICleveland BioLabs initiates colorectal cancer study of entolimod in Russia
Cleveland BioLabs announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naive patients with primary colorectal cancer who are recommended for surgery. The primary objective of the study is to determine the optimal dose and dosing regimen for treatment of these patients with entolimod prior to surgery. Secondary objectives include evaluation of pharmacodynamic parameters, including immune response to single or double administrations of entolimod at varying dose levels. Up to 32 patients are expected to be enrolled in the study, which is being conducted at four leading oncology centers in the Russian Federation. The study is supported by a development contract with the Russian Federation Ministry of Industry and Trade.
January 29, 2016
16:50 EDTCBLICleveland BioLabs files to sell 6.72M shares of common stock for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use